bioRxiv · 10.1101/114298
Whole genome methylation analysis of non-dysplastic Barretts oesophagus that progresses to invasive cancer
Abstract
ObjectiveTo investigate differences in methylation between patients with non-dysplastic Barretts oesophagus who progress to invasive adenocarcinoma and those that do not.\n\nDesignA whole genome methylation interrogation using the Illumina HumanMethylation 450 array of patients with non-dysplastic Barretts Oesophagus who either develop adenocarcinoma or remain static, with validation of findings by bisulfite pyrosequencing\n\nResultsIn total, 12 patients with \"progressive\" vs. 12 with \"non-progressive\" non-dysplastic Barretts oesophagus were analysed via methylation array. Fourty-four methylation markers were identified that may be able to discriminate between non-dysplastic Barretts Oesophagus that either progress to adenocarcinoma or remain static. Hypomethylation of the recently identified tumour supressor OR3A4 (probe cg09890332) validated in a separate cohort of samples (median methylation in progressors = 67.8% vs. 96.7% in non-progressors,p=0.0001, z = 3.85, Wilcoxon rank sum test) and was associated with the progression to adenocarcinoma. There were no differences in copy number between the two groups, but a global trend towards hypomethylation in the progressor group was observed.\n\nConclusionHypomethylation of OR3A4 has the ability to risk stratify the patient with non-dysplastic Barretts Oesophagus and may form the basis of a future surveillance program.
Explore related subjects
Keep this discovery
Dilworth, M. P., Nieto, T., Stockton, J. D., Whalley, C. M., Tee, L., James, J. D., Hallissey, M. T., Hejmadi, R., Trugdill, N., Tucker, O., Beggs, A. D.. 2017-03-06. Whole genome methylation analysis of non-dysplastic Barretts oesophagus that progresses to invasive cancer. https://doi.org/10.1101/114298
Cite the original work for its findings. Save a collection to share your selection of sources.